文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > Anti-cd TCR antibody-expanded cd T cells a better choice
侵权投诉

Anti-cd TCR antibody-expanded cd T cells a better choice

Cellular&MolecularImmunology(2012)9,34–44

ß2012CSIandUSTC.Allrightsreserved1672-7681/12$32.00

doc.guandang.net

RESEARCHARTICLE

Anti-cdTCRantibody-expandedcdTcells:abetterchoicefortheadoptiveimmunotherapyoflymphoidmalignancies

JianhuaZhou,NingKang,LianxianCui,DenianBaandWeiHe

Cell-basedimmunotherapyforlymphoidmalignancieshasgainedincreasingattentionaspatientsdevelopresistancetoconventionaltreatments.cdTcells,whichhavemajorhistocompatibilitycomplex(MHC)-unrestrictedlyticactivity,havebecomeapromisingcandidatepopulationforadoptivecelltransfertherapy.WepreviouslyestablishedastableconditionforexpandingcdTcellsbyusinganti-cdT-cellreceptor(TCR)antibody.Inthisstudy,wefoundthatadoptivetransferoftheexpandedcdTcellstoDaudilymphoma-bearingnudemicesignificantlyprolongedthesurvivaltimeofthemiceandimprovedtheirlivingstatus.Wefurtherinvestigatedthecharacteristicsoftheseantibody-expandedcdTcellscomparedtothemorecommonlyused

phosphoantigen-expandedcdTcellsandevaluatedthefeasibilityofemployingtheminthetreatmentoflymphoidmalignancies.SlowbutsustainedproliferationofhumanperipheralbloodcdTcellswasobserveduponstimulationwithanti-cdTCRantibody.Comparedtophosphoantigen-stimulatedcdTcells,theantibody-expandedcellsmanifestedsimilarfunctionalphenotypesandcytotoxicactivitytowardslymphomacelllines.Itisnoteworthythattheanti-cdTCRantibodycouldexpandboththeVd1andVd2subsetsofcdTcells.Theinvitro-expandedVd1Tcellsdisplayedcomparabletumourcell-killingactivitytoVd2Tcells.Importantly,owingtohigherC–Cchemokinereceptor4(CCR4)andCCR8expression,theVd1TcellsweremorepronetoinfiltrateCCL17-orCCL22-expressinglymphomasthantheVd2Tcells.CharacterizingtheperipheralbloodcdTcellsfromlymphomapatientsfurtherconfirmedthattheanti-cdTCRantibody-expandedcdTcellscouldbeamoreefficaciouschoiceforthetreatmentoflymphoidmalignanciesthanphosphoantigen-expandedcdTcells.

Cellular&MolecularImmunology(2012)9,34–44;doi:10.1038/cmi.2011.16;publishedonline13June2011Keywords:adoptivecelltherapy;anti-cdTCRantibody;cdTcells;lymphoidmalignancies;Vd1subset

INTRODUCTION

Conventionaltherapeuticstrategies,includingchemotherapyandradiotherapy,effectivelysuppresslymphoidmalignanciesduringtheinitialtreatments.However,themajorityofpatientsbecomeresistanttothesetherapies.Therefore,othertherapeuticstrategies,suchascell-basedimmunotherapy,areattractingincreasingattention.1Innateimmunecellsarepromisingcandidatesfortumourimmunotherapybecausetheyplayacriticalroleintumourimmunosurveillance.2

cdTcells,whichfunctioninbothinnateandacquiredimmunity,areconsideredtobepotentcandidatesforimmunotherapy.3,4UnlikeconventionalabTcells,cdTcellscanbeactivatedandexpandedbyseveralphosphorylatednon-peptideantigens(phosphoantigens),includingisopentenylpyrophosphate,bromohydrinpyrophosphate,(E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphateandaminobi-sphosphonates.5Phosphoantigen-activatedcdTcellshavealreadybeentestedinseveralclinicaltrials.Considerableanti-tumoureffectswereoftenobtainedwithoutanysignificanttoxicity.Insomeclinicaltrials,thecdT-cellpopulationwasincreasedthroughinvivocdT-cellexpansionuponphosphoantigenadministration.Studiesinpatientswithsolidtumourshavedemonstratedthattreatmentwithbromohy-drinpyrophosphate(IPH1101)incombinationwithlow-doseinter-leukin2(IL-2)issafeandwell-toleratedandinducespotentcdTlymphocyteexpansioninpatients.6Inanotherclinicaltrial,inpatientswithadvancedbreastcancertreatedwithzoledronateandIL-2,astatisticallysignificantcorrelationbetweenclinicaloutcomeandperi-pheralVc9Vd2Tcellnumbersemerged.7Inaddition,thedirecttrans-ferofinvitro-expandedcdTcellshasbeenusedinsomeclinicaltrialsandwasproventobesafe.8–10Inatrialofadoptivetransferofinvitro-expandedcdTcellstonon-smallcelllungcancerpatients,immu-nomonitoringdatashowedthatthenumberofperipheralcdTcellsgraduallyincreasedwithincreasingnumbersofinfusions.10Potentialanti-tumoureffectshavebeenreportedinsomepatients

DepartmentofImmunology,InstituteofBasicMedicalSciences,ChineseAcademyofMedicalSciencesandSchoolofBasicMedicine,PekingUnionMedicalCollege,NationalKeyLaboratoryofMedicalMolecularBiology,Beijing,China

Correspondence:DrWHe,DepartmentofImmunology,InstituteofBasicMedicalSciences,ChineseAcademyofMedicalSciencesandSchoolofBasicMedicine,PekingUnionMedicalCollege,NationalKeyLaboratoryofMedicalMolecularBiology,Beijing100005,China.E-mail:heweiimu@public.bta.net.cn

DrNKang,DepartmentofImmunology,InstituteofBasicMedicalSciences,ChineseAcademyofMedicalSciencesandSchoolofBasicMedicine,PekingUnionMedicalCollege,NationalKeyLaboratoryofMedicalMolecularBiology,Beijing100005,China.E-mail:n.kang@ibms.pumc.edu.cn

Received16March2011;revised28April2011;accepted3May2011

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email